High-Dose Vitamin D and Falls in Older Adults: Does More Mean Worse?

Vitamin D has been linked for decades to osteoporosis and fall prevention in older adults — rightly so, since deficiency is genuinely associated with weaker muscles, lower bone density, and higher fracture risk, as we describe in more detail in our knowledge-base entry on vitamin D3. From this well-documented relationship, it's easy to draw an intuitive but mistaken conclusion: if deficiency is harmful and vitamin D is safe and cheap, then giving it in higher doses, less often and more conveniently — say, once a month or once a year — should provide at least as much benefit, perhaps even more.

Two independent randomized trials, conducted in different countries, on different populations, with different dosing schedules, show that this assumption is false — and for falls in older adults, actually reversed. High, infrequently administered doses of vitamin D were associated with more falls, not fewer, despite raising blood vitamin D levels more effectively than standard doses. This is one of those cases in medicine where how a goal is reached turns out to matter as much as the goal itself.

The first study was conducted in Zurich, among adults aged 70 and older who had experienced at least one fall in the previous year — a population already at elevated risk, for whom preventing further falls carries particular clinical importance.

If the Swiss result had been a statistical fluke or an artifact of one specific dosing schedule, you might expect a different study, in a different country, with a completely different dosing strategy, not to reproduce the effect. Instead, a much larger Australian trial testing a single annual dose instead of monthly dosing showed the same direction of effect.

The most informative element of the Australian trial isn't simply the increased fall risk itself, but its distribution over time. The risk wasn't spread evenly across the year between doses — it was clearly concentrated in the first three months after each annual mega-dose (rate ratio 1.31), then dropped noticeably over the remaining nine months (rate ratio 1.13), a difference that was statistically significant (P=0.02).

This temporal pattern is an important interpretive clue: if the problem were simply too high a total annual vitamin D level, risk should have been roughly constant throughout the year as long as levels remained elevated. Instead, risk is concentrated exactly in the period when blood vitamin D concentration rises sharply right after a large dose and then gradually declines. This suggests the culprit isn't vitamin D at a stable, established level, but the sharp, transient spike characteristic of bolus dosing.

The exact mechanism by which a sharp rise in vitamin D levels would increase fall risk isn't yet firmly established, but researchers have proposed several hypotheses that aren't mutually exclusive. The first concerns muscle function: vitamin D affects calcium metabolism inside muscle cells, and a sudden, large spike in its concentration could transiently disrupt this regulation differently than a gradual, stable rise from daily dosing.

A second hypothesis concerns calcium balance more broadly — vitamin D increases calcium absorption from the gut, and a sharp spike in its level could lead to transient, acute fluctuations in blood calcium that in turn could affect neuromuscular conduction and the coordination relevant to preventing falls. A third, more general hypothesis holds that for many biological systems dependent on vitamin D, what matters isn't just the target level but the speed at which it's reached — a rapid change may trigger a different physiological response than a slow approach to the same point. None of these hypotheses has yet been conclusively confirmed experimentally as the sole mechanism, but all are consistent with the observed temporal pattern of risk.

This same general pattern — that a more convenient, less frequent, high-dose schedule isn't simply a "compressed" version of daily supplementation with identical effects — had already appeared in other areas of vitamin D research, including some analyses of upper respiratory infections, where the protective effect was seen mainly with daily or weekly dosing and was weaker or absent with large, infrequent boluses. This strengthens the conclusion that the practical convenience of infrequent dosing carries a biological cost that isn't always visible in a simple blood-level measurement.

Some older adults, particularly those with diagnosed deficiency, receive a regimen from their doctor built around exactly this kind of large, infrequent dose — for example, a single "loading" dose of tens or hundreds of thousands of IU meant to rapidly correct a severe deficiency. The results discussed here don't mean such a regimen is always wrong — it can be clinically justified in specific, acute deficiency situations — but they are a strong argument against using large, infrequent doses routinely, long-term, as a more convenient alternative to daily supplementation in older adults at risk of falls.

It's rare for two independent randomized trials, in two different countries, with two different dosing schedules (monthly and annual), across two different older-adult populations, to show such a consistent — and simultaneously counterintuitive — picture. It's precisely this convergence, together with the clear, mechanistically plausible temporal pattern of risk in the Australian trial, that makes this topic credible and worth raising with a doctor when discussing a supplementation regimen for older adults — especially those with a history of falls or elevated fracture risk.